The molecular biology of poliovaccines

References

1. Assaad F., Cockburn W. C. 1982; The relation between acute persisting spinal paralysis and poliomyelitis vaccine — result of a ten-year enquiry. Bulletin of the World Health Organization 60:231–242
   [Google Scholar]
2. Assaad F., Ljungars-Esteves K. 1984; World overview of poliomyelitis: regional patterns and trends. Reviews of Infectious Diseases 6: supplement 2S302–S307
   [Google Scholar]
3. Cammack N., Phillips A., Dunn G., Patel V., Minor P. D. 1989; Intertypic genomic rearrangements of poliovirus strains in vaccinees. Virology 167:507–514
   [Google Scholar]
4. Cann A. J., Stanway G., Hughes P. J., Minor P. D., Evans D. M. A., Schild G. C., Almond J. W. 1984; Reversion to virulence of the live attenuated Sabin type 3 oral poliovirus vaccine. Nucleic Acids Research 12:7787–7792
   [Google Scholar]
5. Christodoulou C., Colbere-Garapin F., Macadam A., Taffs L. F., Marsden S., Minor P. D., Horaud F. 1990; Mapping of mutations associated with monkey neurovirulence of Sabin 1 poliovirus revertants selected at high temperature. Journal of Virology 64:4922–4929
   [Google Scholar]
6. Chumakov K. M., Powers L. B., Newman K. E., Robinson I. B., Levenbook I. S. 1991; Correlation between amount of virus with altered nucleotide sequence and the monkey test for acceptability of oral poliovirus vaccine. Proceedings of the National Academy of Sciences, U.S.A. 88:199–203
   [Google Scholar]
7. Chumakov K. M., Norwood L. P., Parker M. L., Dragunsky E. M., Ran Y., Levenbook I. S. 1992; RNA sequence variants in live poliovirus vaccine and their relation to neurovirulence. Journal of Virology 66:966–970
   [Google Scholar]
8. Dunn G., Begg N. T., Cammack N., Minor P. D. 1990; Virus excretion and mutation by infants following primary vaccination with live oral poliovaccine from two sources. Journal of Medical Virology 32:92–95
   [Google Scholar]
9. Evans D. M. A., Dunn G., Minor P. D., Schild G. C., Cann A. J., Stanway G., Almond J. W., Currey K., Maizel J. V. 1985; A single nucleotide change in the 5′ non-coding region of the genome of the Sabin type 3 poliovaccine is associated with increased neurovirulence. Nature, London 314:548–550
   [Google Scholar]
10. Filman D. J., Syed R., Chow M., Minor P. D., Macadam A. J., Hogle J. 1989; Structural factors that control conformational transitions and serotype specificity in type 3 poliovirus. EMBO Journal 8:1567–1579
    [Google Scholar]
11. Ghalioungui P. 1973 The House of Life 2nd edn, plate 21, p 154 Edited by Israel B. M.
    [Google Scholar]
12. Hogle J. M., Chow M., Filman D. J. 1985; The three-dimensional structure of poliovirus at 2.9 A resolution. Science 229:1358–1365
    [Google Scholar]
13. Hughes P. J., Evans D. M. A., Minor P. D., Schild G. C., Almond J. W., Stanway G. 1986; The nucleotide sequence of a type 3 poliovirus isolated during a recent outbreak of poliomyelitis in Finland. Journal of General Virology 67:2093–2102
    [Google Scholar]
14. La Monica N., Racaniello V. R. 1989; Difference in replication of attenuated and neurovirulent polioviruses in human neuroblastoma cell line SH-SYSY. Journal of Virology 63:2357–2360
    [Google Scholar]
15. Lee C., Wimmer E. 1988; Proteolytic processing of poliovirus polyprotein: elimination of 2A^Pro mediated alternative cleavage of polypeptide 3CD by in vitro mutagenesis. Virology 166:405–414
    [Google Scholar]
16. Lee S.-Y., Zuker M. 1990; Common structures of the 5′ non-coding RNA in enteroviruses and rhinoviruses. Journal of Molecular Biology 216:729–741
    [Google Scholar]
17. Lipskaya G. Y., Muzychenko A. R., Kutilova O. K., Maslona S. V., Equeste M., Drozdov S. G., Perez-Beroff R., Agol V. I. 1991; Frequent isolation of intertypic poliovirus recombinants with serotype 2 specificity from vaccine-associated polio cases. Journal of Medical Virology 35:290–296
    [Google Scholar]
18. Macadam A. J., Arnold C., Howlett J., John A., Marsden S., Taffs F., Reeve P., Hamada N., Wareham K., Almond J., Cammack N., Minor P. D. 1989; Reversion of attenuated and temperature-sensitive phenotypes of the Sabin type 3 strain of poliovirus in vaccinees. Virology 174:408–414
    [Google Scholar]
19. Macadam A. J., Ferguson G., Arnold C., Minor P. D. 1991a; An assembly defect as a result of an attenuating mutation in the capsid protein of the poliovirus type 3 vaccine strain. Journal of Virology 72:2475–2481
    [Google Scholar]
20. Macadam A. J., Pollard S. R., Ferguson G., Dunn G., Skuce R., Almond J. W., Minor P. D. 1991b; The 5′ non-coding region of the type 2 poliovirus vaccine strain contains determinants of attenuation and temperature sensitivity. Virology 181:451–158
    [Google Scholar]
21. Macadam A. J., Ferguson G., Burlington J., Stone D., Skuce R., Almond J. W., Minor P. D. 1992; Correlation of RNA structure and attenuation of Sabin vaccine strains of poliovirus in tissue culture. Virology (in press)
    [Google Scholar]
22. Minor P. D. 1980; Comparative biochemical studies of type 3 polioviruses. Journal of Virology 34:73–84
    [Google Scholar]
23. Minor P. D., Dunn G. 1988; The effect of sequences in the 5′ non-coding region on the replication of polioviruses in the human gut. Journal of General Virology 69:1091–1096
    [Google Scholar]
24. Minor P. D., Schild G. C. 1981; Identification of the origin of poliovirus isolates. Report of World Health Organization Informal Meetings 1978–1980. Lancet i:968–969
    [Google Scholar]
25. Minor P. D., John A., Ferguson M., Icenogle J. P. 1986; Antigenic and molecular evolution of the vaccine strain of type 3 poliovirus during the period of excretion by a primary vaccinee. Journal of General Virology 67:693–706
    [Google Scholar]
26. Minor P. D., Dunn G., Evans D. M. A., Magrath D. I., John A., Howlett J., Phillips A., Westrop G., Wareham K., Almond J. W., Hogle J. M. 1989; The temperature sensitivity of the Sabin type 3 vaccine strain of poliovirus: molecular and structural effects of a mutation in the capsid protein VP3. Journal of General Virology 70:1117–1123
    [Google Scholar]
27. Nkowane B. M., Wassilak S. G., Oversteen W. A., Bart K. J., Schonberger L. B., Hinman A. R., Kew O. M. 1987; Vaccine-associated paralytic poliomyelitis in the United States: 1973 through 1984. Journal of the American Medical Association 257:1335–1340
    [Google Scholar]
28. Nomoto A., Omata T., Toyoda H., Kuge S., Horie H., Kataoka Y., Genba Y., Nakano Y., Imura N. 1982; Complete nucleotide sequence of the attenuated poliovirus Sabin 1 strain genome. Proceedings of the National Academy of Sciences, U.S.A. 79:5793–5797
    [Google Scholar]
29. Nottay B. K., Kew O. M., Hatch M. H., Hayward J. I., Obijeski J. F. 1981; Molecular variation of type 1 vaccine-related and wild polioviruses during replication in humans. Virology 108:405–423
    [Google Scholar]
30. Omata T., Kohara M., Kuge S., Komatsu T., Abe S., Semler B. L., Kameda A., Itoh H., Arita M., Wimmer E., Nomoto A. 1986; Genetic analysis of the attenuation phenotype of polio-virus type 1. Journal of Virology 58:348–358
    [Google Scholar]
31. Pelletier J., Sonenberg N. 1988; Internal initiation of translation of eukaryotic mRNA directed by a sequence derived from poliovirus RNA. Nature, London 334:320–325
    [Google Scholar]
32. Pilipenko E. V., Blinov V., Romanova L. I., Sinyakov A. N., Maslova S. V., Agol V. I. 1989; Conserved structural domains in the 5′ untranslated region of picomaviral genomes. An analysis of the segment controlling translation and neurovirulence. Virology 168:201–209
    [Google Scholar]
33. Pollard S. R., Dunn G., Cammack N., Minor P. D., Almond J. W. 1989; Nucleotide sequence of a neurovirulent variant of the type 2 oral poliovirus vaccine. Journal of Virology 63:4949–4951
    [Google Scholar]
34. Racaniello V. R., Baltimore D. 1981; Cloned poliovirus complementary DNA is infectious in mammalian cells. Science 214:916–919
    [Google Scholar]
35. Ren R., Moss E. G., Racaniello V. R. 1991; Identification of two determinants that attenuate vaccine-related type 2 poliovirus. Journal of Virology 65:1377–1382
    [Google Scholar]
36. Rico-Hesse R., Pallansch M. A., Nottay B. K., Kew O. M. 1987; Geographic distribution of wild poliovirus type 1 genotypes. Virology 160:311–322
    [Google Scholar]
37. Rivera W. M., Welsh J. D., Maizel J. V. Jr 1988; Comparative sequence analysis of the 5′ non-coding region of the enteroviruses and rhinoviruses. Virology 165:42–50
    [Google Scholar]
38. Sabin A. B., Boulger L. R. 1973; History of Sabin attenuated poliovirus oral live vaccine strains. Journal of Biological Standardization 1:115–118
    [Google Scholar]
39. Salk J. E. 1960; Persistence of immunity after administration of formalin-treated poliovirus vaccine. Lancet ii:715–723
    [Google Scholar]
40. Skinner M. A., Racaniello V. R., Dunn G., Cooper J., Minor P. D., Almond J. W. 1989; A new model for the secondary structure of the 5′ non-coding RNA of poliovirus is supported by biochemical and genetical data which also show that RNA secondary structure is important in neurovirulence. Journal of Molecular Biology 207:379–392
    [Google Scholar]
41. Stanway G. 1990; Structure, function and evolution of picorna-viruses. Journal of General Virology 71:2483–2501
    [Google Scholar]
42. Stanway G., Hughes P. J., Mountford R. C., Reeves P., Minor P. D., Schild G. C., Almond J. W. 1984; Comparison of the complete nucleotide sequence of the genomes of the neurovirulent poliovirus P3/Leon/37 and its attenuated Sabin vaccine derivative P3/Leon/12a, b. Proceedings of the National Academy of Sciences, U.S.A. 81:1539–1543
    [Google Scholar]
43. Svitkin Y. V., Maslova S. V., Agol V. I. 1985; The genomes of attenuated and virulence poliovirus strains differ in their in vitro translation efficiences. Virology 147:243–252
    [Google Scholar]
44. Svitkin Y. V., Pestova T. V., Maslova S. V., Agol V. I. 1988; Point mutations modify the response of poliovirus RNA to a translation or initiation factor: a comparison of neurovirulence and attenuated strains. Virology 166:394–404
    [Google Scholar]
45. Svitkin Y., Cammack N., Minor P. D., Almond J. W. 1990; Translation deficiency of the Sabin type 3 poliovirus genome: association with an attenuating mutation C472-V. Virology 175:103–109
    [Google Scholar]
46. Tatem J. M., Weeks-Levy C., Georgiu A., DiMichele S. J., Gogaez E. J., Racaniello V. R., Cano F. R., Mento S. J. 1992; A mutation present in the amino terminus of Sabin 3 polio-virus VP1 protein is attenuating. Journal of Virology 66:3194–3197
    [Google Scholar]
47. Toyoda H., Kohara M., Kastaoka Y., Suganuma T., Imura N., Nomoto A. 1984; Complete nucleotide sequence of all three poliovirus serotype genomes: implications for genetic relationship, gene function and antigenic determinants. Journal of Molecular Biology 124:561–595
    [Google Scholar]
48. Van der Werf S., Bradley J., Wimmer E., Studier F. W., Dunn J. J. 1986; Synthesis of infectious poliovirus RNA by purified T7 polymerase. Proceedings of the National Academy of Sciences, U.S.A. 83:2330–2334
    [Google Scholar]
49. Weeks-Levy C., Tatem J. M., DiMichele S. J., Waterfield W., Georgiu A. F., Mento S. J. 1991; Identification and characterization of a new base substitution in the vaccine strain of Sabin 3 poliovirus. Virology 185:934–937
    [Google Scholar]
50. Westrop G. D., Evans D. M. A., Dunn G., Minor P. D., Magrath D. I., Taffs F., Marsden S., Wareham K. A., Skinner M., Schild G. C., Almond J. W. 1989; Genetic basis of attenuation of the Sabin type 3 oral poliovaccine. Journal of Virology 63:1338–1344
    [Google Scholar]
51. WHO 1969; Evidence on the safety and efficacy of live poliomyelitis vaccines currently in use, with special reference to type 3 poliovirus. Bulletin of the World Health Organization 40:925–945
    [Google Scholar]
52. WHO 1983; Requirements for poliomyelitis vaccine (oral) (Revised 1982). Technical Report Series 687107–174 Geneva: World Health Organization;
    [Google Scholar]